AlphaYou
Overview
Key stats
Fundamentals Sep 9- Open
- $114.20
- 52-wk high
- $126.38
- High
- $117.50
- 52-wk low
- $28.66
- Low
- $113.77
- Prev close
- $113.98
- Mkt cap
- $12.32B
- P/E
- 253.3x
- Volume
- 572.0K
- Fwd P/E
- 18.4x
- Beta
- 0.45
- P/S
- 14.8x
- P/B
- 17.1x
- Profit margin
- +6.6%
- Op margin
- +16.1%
- ROE
- +8.2%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Earnings
Earnings came in $0.40 a share above what analysts expected.
Earnings per share
-$0.04 expected
Reports Nov 3, 2026, in 54 days
EPS expected
$0.74 to $1.03
Revenue expected
4 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $207.6M | $202.1M | $164.9M | $256.1M |
| Cost of what it sold | $4.6M | $2.5M | $2.9M | $4.1M |
| Gross profit | $203.0M | $199.6M | $162.0M | $252.1M |
| What it spent | ||||
| Research and development | $68.8M | $64.9M | $66.3M | $53.9M |
| Sales and admin | $124.0M | $130.2M | $145.4M | $156.9M |
| Total operating expenses | $192.8M | $195.1M | $211.6M | $210.8M |
| What was left | ||||
| Operating profit | $10.2M | $4.5M | -$49.6M | $41.3M |
| Profit before tax | $15.2M | $9.9M | -$44.7M | $45.9M |
| Tax | -$4.4M | -$14.4M | -$13.5M | -$2.9M |
| Net profit | $19.7M | $24.3M | -$31.2M | $42.1M |
| EBITDA | $15.7M | $10.4M | -$44.1M | $46.8M |
Technicals
Price structure
This stock is trending upward.
Trend
Constructive
65 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage leans bearish
Tone of tracked coverage
Corcept Therapeutics oncology president sells $6.46m in shares
NeutralSep 5Corcept Therapeutics Insider Sold Shares Worth $6,460,766, According to a Recent SEC Filing
Leans bearishSep 4Corcept president Sean Maduck sells $2.86m in stock
NeutralSep 4CORCEPT Therapeutics Officer Vieira Roberto Wandenkolk to Sell 75,295 Shares Including 74,999 Stock Options (NASDAQ: CORT)
NeutralSep 3Corcept Therapeutics Director Kimberly Park Reports Stock Option Exercise and Sale in SEC Form 4 Filing
NeutralAug 29Corcept Therapeutics' Sean Maduck Executes Stock Option Exercise and Sells Shares Under 10b5-1 Plan
NeutralAug 28